MorphoSys AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
MorphoSys AG - overview
Established
1992
Location
Planegg, -, Germany
Primary Industry
Biotechnology
About
Founded in 1992 and based in Planegg, Germany, MorphoSys AG is a biotechnology company that mainly develops and provides pharmaceutical medicine for cancer diseases. It was founded in Martinsried, Germany by Dr. Simon Moroney and Prof. Dr.
Andreas Plückthun. Initially, MorphoSys served as an R&D technology provider, but it quickly evolved into a biopharmaceutical powerhouse. MorphoSys has forged multiple partnerships and collaborations with many pharmaceutical companies such as Novartis, Janssen, Schering-Plough, Pfizer, and Merck over the years. In February 2024, Novartis International AG agreed to acquire MorphoSys AG from Royalty Pharma Plc for EUR 2.
7 billion or EUR 68 per share in cash in a public-to-private transaction. MorphoSys has leveraged its proprietary HuCAL technology to build a diverse pipeline of therapeutic antibody candidates. The company's lead product, Monjuvi (tafasitamab-cxix), is a humanized monoclonal antibody approved for the treatment of diffuse large B-cell lymphoma, a type of blood cancer. Monjuvi was developed in collaboration with Incyte Corporation and generated net product sales of $92 million in 2023.
In addition to Monjuvi, MorphoSys has several other drug candidates in its pipeline. Pelabresib, an investigational BET inhibitor, as of 2024, is in Phase 3 clinical trials for the treatment of myelofibrosis, a rare and serious blood cancer. Tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, is being evaluated in a Phase 2 study for the treatment of advanced solid tumors and hematologic malignancies in 2024. MorphoSys's revenue streams include product sales, royalties, and licensing agreements.
The company also generates revenue from licensing its HuCAL technology to other pharmaceutical and biotechnology companies. The acquisition in 2024 will help MorphoSys AG to continuously enhance its pharmaceutical production, and accelerate its product opportunities in the biotechnology sectors.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.morphosys.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
MorphoSys AG - timeline of key events
MorphoSys AG - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 87,036,308 | 100,777,157 | 51,916,986 | 77,960,057 | 63,977,978 | 106,222,897 | 49,743,515 | 66,790,840 | 76,442,505 | 71,755,303 | 327,698,465 | - | - | - |
| % Revenue Growth (YoY) | - | 15.8% | (48.5%) | 50.2% | (17.9%) | 66.0% | (53.2%) | 34.3% | 14.5% | (6.1%) | 356.7% | - | - | - |
| EBITDA (USD) | 15,969,088 | 18,786,576 | 8,802,550 | 14,758,994 | (1,764,089) | 20,689,174 | (56,177,180) | (63,578,701) | (55,355,834) | (101,674,419) | 35,690,757 | - | - | - |
| Operating Income (USD) | 9,848,763 | 12,157,797 | 2,492,015 | 9,924,547 | (5,898,568) | 17,234,332 | (59,940,993) | (67,607,649) | (59,106,093) | (107,919,581) | 27,361,198 | - | - | - |
| Operating Margin | 11.3% | 12.1% | 4.8% | 12.7% | (9.2%) | 16.2% | (120.5%) | (101.2%) | (77.3%) | (150.4%) | 8.3% | - | - | - |
| % EBITDA Margin | 18.3% | 18.6% | 17.0% | 18.9% | (2.8%) | 19.5% | (112.9%) | (95.2%) | (72.4%) | (141.7%) | 10.9% | - | - | - |
| NET Income (USD) | 9,196,300 | 8,216,397 | 1,942,145 | 13,321,930 | (3,012,629) | 14,900,768 | (60,382,776) | (69,826,469) | (56,172,121) | (103,014,058) | 97,890,576 | - | - | - |
| % Net Margin | 10.6% | 8.2% | 3.7% | 17.1% | (4.7%) | 14.0% | (121.4%) | (104.5%) | (73.5%) | (143.6%) | 29.9% | - | - | - |
MorphoSys AG - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | MorphoSys AG | - |
Displaying 1 - 1 of 1
MorphoSys AG - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.